Back to Search
Start Over
The druggable genome: Evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication.
- Source :
-
Annual review of pharmacology and toxicology [Annu Rev Pharmacol Toxicol] 2014; Vol. 54, pp. 9-26. Date of Electronic Publication: 2013 Aug 30. - Publication Year :
- 2014
-
Abstract
- The largest innovations within pharmaceutical development come through new compounds that have unique and novel modes of action. These innovations commonly involve expanding the protein space targeted by pharmaceutical agents. At present, information about drugs and drug targets is available online via public databases such as DrugBank and the Therapeutic Targets Database. However, this information is biased, understandably so, toward established drugs and drug-target interactions. To gain a better overview of the drug-targeted portion of the human proteome and the directions of current drug development, we developed a data set of clinical trial drug-target interactions based on CenterWatch's Drugs in Clinical Trials Database, one of the largest databases of its kind. Our curation identified 475 potentially novel clinical trial drug targets. This review aims to identify trends in drug development based on the potentially novel targets currently being explored in clinical trials.
- Subjects :
- Alzheimer Disease drug therapy
Anti-Inflammatory Agents pharmacology
Antineoplastic Agents pharmacology
Appetite Regulation drug effects
Clinical Trials as Topic
Databases, Factual
Evaluation Studies as Topic
G-Protein-Coupled Receptor Kinases genetics
G-Protein-Coupled Receptor Kinases metabolism
Humans
Hypoglycemic Agents pharmacology
Proteome metabolism
Genome, Human
Molecular Targeted Therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1545-4304
- Volume :
- 54
- Database :
- MEDLINE
- Journal :
- Annual review of pharmacology and toxicology
- Publication Type :
- Academic Journal
- Accession number :
- 24016212
- Full Text :
- https://doi.org/10.1146/annurev-pharmtox-011613-135943